For example, the initial clinical trial evaluating the anti-TGF-β monoclonal antibody SAR439459 in patients suffering from advanced solid tumors, which juxtaposed tumor biopsies against peripheral blood samples, observed consistent declines in TGF-β levels, thereby meeting the anticipated outcomes. Here, TGFB1 is linked to neoplasm.